



Perspective article

Proteasome Activity in Parkinsonism through D1 Dopamine Receptor

R.B. Jiménez^a, J.E. Telich-Tarriba^a, J.D. Carrillo-Ruíz^{b,c}, G. Rivera-Silva^d

^aNeuroscience and Biotechnology Laboratory, School of Medicine, Universidad Panamericana, México DF, México.

^bDepartment of Neuroscience and Psychophysiology, Universidad Anahuac, Mexico City.

^cNeurosurgery Clinic of Spasticity, Service Functional Neurosurgery and Radiosurgery Hospital General de México O.D.

^dTisular Engineering and Regenerative Medicine Laboratory, University of Monterrey, San Pedro Garza García, NL, México.

*Corresponding author; Neuroscience and Biotechnology Laboratory, School of Medicine, Universidad Panamericana, México DF, México.

ARTICLE INFO

Article history:

Received 03 December 2012

Accepted 28 December 2012

Available online 29 January 2013

Keywords:

L-DOPA

Antiparkinsonian drugs

Ubiquitine-proteasome system

Akinetic symptoms

ABSTRACT

As of today, L-DOPA is recognized as the most efficacious drug to alleviate the typical signs and symptoms of Parkinson disease (PD). It is most effective for the akinetic symptoms, and its use is indicated when the disease becomes disabling or it cannot be controlled by other antiparkinsonian drugs. Unfortunately, response to medication changes during the progression of the disease, with the patients developing tolerance to treatment and the need for higher doses that lead to the development of side effects. The Ubiquitine-proteasome system (UPS) is key in regulating the degradation of normal and abnormal intracellular proteins linked to signal transduction, cell cycle progression, apoptosis and differentiation; therefore its dysregulation would be expected to impact several systems. UPS dysregulation has been implicated in cancer, neurodegenerative and autoimmune diseases.

© 2013 Sjournals. All rights reserved.

As of today, L-DOPA is recognized as the most efficacious drug to alleviate the typical signs and symptoms of Parkinson disease (PD). It is most effective for the akinetic symptoms, and its use is indicated when the disease becomes disabling or it cannot be controlled by other antiparkinsonian drugs. Unfortunately, response to medication changes during the progression of the disease, with the patients developing tolerance to treatment and the need for higher doses that lead to the development of side effects (Francois, 2009).

A considerable amount of patients end up developing L-DOPA induced complications within several years of starting treatment; these may include motor fluctuations, dystonia, and most importantly dyskinesia. It is estimated that about 40% of patients develop dyskinesia after 5 years of therapy, with the figure surpassing the 60% by 10 years (Ahlskog and Muentner, 2001).

Pathophysiology of L-DOPA-induced dyskinesia (LID) remains unclear. Most knowledge concerns alterations in the basal ganglia circuitry signaling, with maladaptive neuroplasticity postsynaptic dopamine receptors and transporters, most likely due to secondary to the nonphysiologic fluctuations in plasmatic dopamine levels in patients treated with L-DOPA (Troiano et al., 2009).

Prevention and treatment of LID has become a central focus for basic and clinical PD researchers. Studies on animal models, especially rodents and nonhuman primates, reveal interesting aspects of this complex entity, and have allowed researchers to elucidate some of the main mechanisms involved. A recent article by Bethet et al. published in the *Journal of Neuroscience* proposed that dysregulation in D1 dopamine receptor (D1R) in PD patients treated chronically with L-DOPA is associated with impaired proteasome activity. In order to prove it, rodent and primate sporadic PD models were used, comparing proteasome activity between subjects receiving L-DOPA treatment, placebo or left untreated. The research team was able to identify prove that parkinsonian animals with chronic L-DOPA treatment developed striatum-specific decrease in proteasome chymotrypsin-like catalytic activity dependent on D1R activation. Therefore, D1R can be identified as the first step leading to inhibited catalytic activity and intraneural accumulation of proteins (Berthet et al., 2012).

The Ubiquitin-proteasome system (UPS) is key in regulating the degradation of normal and abnormal intracellular proteins linked to signal transduction, cell cycle progression, apoptosis and differentiation; therefore its dysregulation would be expected to impact several systems. UPS dysregulation has been implicated in cancer, neurodegenerative and autoimmune diseases.

The role of UPS dysregulation in PD pathogenesis has been evidenced by multiple authors, with the detection of decreased proteasome activity and accumulation of ubiquitinated proteins in the substantia nigra of PD patients, and the observation that subjects receiving proteasome inhibitors may replicate parkinsonian symptoms (Cook et al., 2009). However the originality of Bethet's research lies in the fact that it proves UPS dysregulation is directly linked to L-DOPA, rather than it just being inherent to PD.

We must take into account that although these new findings are encouraging, they are only but one part of the whole spectrum of dysregulations in the synapse that must take place for the development of LID. For example, Troiano et al. have found that the onset of dyskinesias coincides with a downregulation in presynaptic dopamine transporters, leading to oscillating levels of DA at the synaptic cleft (Troiano et al., 2009), and probably contributing to alterations in postsynaptic regulation. L-dopa treatment also induces sprouting of serotonin axon terminals in the dopamine-denervated striatum. Remarkable postsynaptic changes after chronic L-DOPA intake include dysfunctions in NMDA receptors and maladaptive plasticity of serotonin axon terminals (Bageetta et al., 2010; Rylander et al., 2010).

As our knowledge of the mechanisms involved in the development of LID increases, new therapeutic approaches may be attempted. Bethel et al. have an interesting proposal: if proteasome inhibition leads to the development of parkinsonian symptoms, would the increase in proteasome activity decrease them? So far no medication is known to have this effect, but it would undoubtedly be an interesting and novel approach to PD therapeutics. Opening a new array of possible therapeutical targets for LID focused on improving proteasome function.

References

- Ahlskog, J.E., Muentner, M.D., 2001. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. *Mov Disord.*16(3), 448.
- Bageetta, V., Ghiglieri, V., Sgobio, C., Calabresi, P., 2010. Picconi B. Synaptic dysfunction in Parkinson's disease. *Biochem Soc Trans.* 38(2), 493-7.

- Berthet, A., Bezard, E., Porras, G., Fasano, S., Barroso-Chinea, P., Dehay, B., Martinez, A., Thiolat, M.L., Nosten-Bertrand, M., Giros, B., Baufreton, J., Li, Q., Bloch, B., Martin-Negrier, M.L., 2012. L-DOPA impairs proteasome activity in parkinsonism through D(1) dopamine receptor. *J Neurosci.* 11, 32(2), 681-91.
- Cook, C., Petrucelli, L.A., 2009. Critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. *Biochim Biophys Acta.* 1792(7), 664-675.
- Francois, J.G., 2009. Vingerhoets. Dyskinesia in Parkinson disease: Back for the future? *Neurol.* 72, 1202-1203.
- Rylander, D., Parent, M., O'Sullivan, S.S., Dovero, S., Lees, A.J., Bezard, E., Descarries, L., 2010. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. *Ann Neurol.* 68(5). 619-28.
- Troiano, A.R., de la Fuente-Fernandez, R., Sossi, V., Schulzer, M., Mak, E., Ruth, T.J., Stoessl, A.J., 2009. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. *Neurol.* 72, 1211 – 1216.